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Abstract
The hERG potassium channel is essential for repolarization of the cardiac action potential. Due to this vital function,
absence of unintended and potentially life-threatening interactions with hERG is required for approval of new drugs.
The structure of hERG is therefore one of the most sought-after. To provide purified hERG for structural studies and
new hERG biomimetic platforms for detection of undesirable interactions, we have developed a hERG expression
platform generating unprecedented amounts of purified and functional hERG channels. Full-length hERG, with or
without a C-terminally fused green fluorescent protein (GFP) His8-tag was produced from a codon-optimized hERG
cDNA in Saccharomyces cerevisiae. Both constructs complemented the high potassium requirement of a knock-out
Saccharomyces cerevisiae strain, indicating correct tetramer assembly in vivo. Functionality was further demonstrated
by Astemizole binding to membrane embedded hERG-GFP-His8 with a stoichiometry corresponding to tetramer
assembly. The 156 kDa hERG-GFP protein accumulated to a membrane density of 1.6%. Fluorescence size exclusion
chromatography of hERG-GFP-His8 solubilized in Fos-Choline-12 supplemented with cholesteryl-hemisuccinate and
Astemizole resulted in a monodisperse elution profile demonstrating a high quality of the hERG channels.
hERG-GFP-His8 purified by Ni-affinity chromatography maintained the ability to bind Astemizole with the correct
stoichiometry indicating that the native, tetrameric structure was preserved. To our knowledge this is the first
reported high-yield production and purification of full length, tetrameric and functional hERG. This significant
breakthrough will be paramount in obtaining hERG crystal structures, and in establishment of new high-throughput
hERG drug safety screening assays.
Keywords: hERG, Potassium channel, Membrane protein production and purification, Functional expression, Yeast,
Cardiac action potential, Drug screening, Long QT, Torsades de Pointes
Background
The lack of high resolution structures is a common theme
among membrane proteins. In contrast to the more than
90,000 structures known for water soluble proteins [1],
only 512 membrane protein structures have been deter-
mined so far [2] (December 2014). This bias is also
reflected by the fact that membrane proteins constitute
around 30% of all proteins [3], and that 60% of all known
drugs target a membrane protein. Similarly, membrane
proteins are the most prominent targets for new drugs [4].
*Correspondence: papedersen@bio.ku.dk
2Department of Biology, University of Copenhagen, Universitetsparken 13,
DK- 2100 Copenhagen OE, Denmark
Full list of author information is available at the end of the article
Thus, the need to increase our understanding of mem-
brane proteins is crucial. Potassium channels constitute
a particularly interesting family of membrane proteins as
they are very important targets for various neuropatholo-
gies [5] and heart conditions [6] as reviewed recently in
Tian et al. 2014 [7]. Consequently, there is a great interest
in solving the structures of these and other ion chan-
nels. However, such studies are impaired by difficulties
in recombinant production of large amounts of func-
tional channels, and establishment of optimal conditions
for purification of stable and functional protein. Thus far,
high resolution structures of fourteen different K+ chan-
nels are available, out of which seven are of archaic and
bacterial origin, seven mammalian and of these only three
are human [2] (December 2014).
© 2015 Molbaek et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication
waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise
stated.
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The human Ether-a`-go-go related gene hERG encodes
the pore forming α-subunit of a voltage gated potas-
sium channel [8]. The hERG channel is most abundantly
expressed in the heart where the channel is involved in
repolarization of the cardiac action potential, by con-
ducting the rapid component of the delayed rectifier
potassium current, IKr [9]. HERG is also expressed in
brain [10], intestine [11,12] and in the endocrine sys-
tem [13]. The hERG channel has been the focus of much
attention due to the identification of hERG mutations
[14] that cause severe heart conditions such as long
QT syndrome and Torsades de Pointes. Similarly, the
hERG channel has been shown to interact with a vari-
ety of structurally diverse drugs, some of which caused
fatal arrhythmias, and have been withdrawn from the
market [15]. Consequently it has become a requirement
by the U.S. food and drug administration (FDA) and
the European Medicines Agency (EMEA) to analyze the
activity of hERG in presence of potential new drugs
[16,17].
The fully assembled channel, termed Kv.11.1., is a
homotetrameric complex of the 1159 amino acids hERG
α-subunit [8]. Figure 1 illustrates that each subunit has
six transmembrane segments (TM1 through TM6), a
403 amino acids N-terminal and a 500 amino acids C-
terminal. The pore loop between TM5 and TM6 [18]
carries the canonical K+ channel sequence SVGFG, that
along with TM5 and TM6 comprise the K+ selective pore
of the protein [1]. The four charged arginine residues
mainly responsible for voltage sensing are located in
TM4 [19]. The cytosolic N- and C-terminal domains are
believed to encompass a Per-Arnt-Sim (PAS) domain [20]
and a cyclic nucleotide binding domain cNBD, respec-
tively [8].
Although the great importance of hERG in heart phys-
iology and drug development has long been recognized,
the three dimensional atomic resolution structure of the
entire 1159 amino acid channel protein has not yet been
determined. Thus, structural insight into the molecu-
lar mechanism of hERG function has been restricted to
homology models based on crystal structures of simi-
lar voltage gated K+ channels such as the significantly
shorter (282 amino acids) KvAP channel from the archae
Aeropyrum pernix [21] and the 499 amino acids Kv1.2
K+ channel from rat [22]. However, the N-terminal 135
residues of hERG has been crystallized revealing that
both gating and subunit assembly are associated with
this part of the protein [20]. Consequently, character-
ization of hERG has been restricted to electrophysiol-
ogy [23], flux measurements [24] and ligand binding
[25].
Protein chemical and structural studies of hERG have
been hampered by lack of expression systems that can
provide large quantities of functional hERG protein
in its active tetrameric form. Purification of recombi-
nant, full-length hERG from Sf9 insect cells resulted in
monomeric hERG subunits, which seemed to be cor-
rectly folded but non-functional [26]. A protein fusion
approach that stabilizes the tetrameric structure of hERG
was recently presented [27]. In this study, a heavily engi-
neered channel in which important parts of the chan-
nel were replaced with a dimerization domain from the
yeast Gcn4 transcription factor was produced in HEK
cells and shown to maintain its tetrameric structure dur-
ing purification. Another approach involved replacing
the transmembrane segments of Kv1.2 with TM1-TM6
from hERG and expression in Pichia pastoris [28]. How-
ever, the hERG cytosolic N- and C-termini were absent,
the expressed S1-S6 chimaeras were partly glycosylated
and the purified chimaeras contained degradation prod-
ucts. Cell-free biosynthesis and subsequent incorporation
into biomimetic membranes have also been demonstrated
using the same TM1-TM6-domain [29]. The ability of the
membrane embedded hERG fragments to bind known
inhibitors suggests potential applications in drug screen-
ing. However, exclusion of the N- and C-terminal residues
involved in the gating mechanism and subunit assembly
may be a draw back. In the present study we demon-
strate that substantial amounts of full length, functional
and tetrameric hERG can be produced in our S. cerevisiae
high-copy vector expression system [30-32].We show that
the recombinant hERG channel can be purified in its
native, functional tetrameric form. To our knowledge this
is the first successful purification of functional tetrameric
hERG channels. This may facilitate crystallization and
biochemical characterization of this important channel
and serve as starting point for inexpensive large scale
biomimetic high-throughput screening systems for identi-
fication of drug candidates free of unintended interactions
with hERG.
Results
hERG expression plasmids
In order to maximize the yield of the hERG-TEV-GFP-
His8 and hERG-His10 fusion proteins we constructed the
expression plasmids outlined in Figure 2. Each fusion
is expressed from a strong galactose inducible CYC-
GAL promoter whose activity is further enhanced in the
host strain PAP1500 through regulated overexpression
of the Gal4 transcriptional activator [30]. To increase
hERG protein production the vector carries the crip-
pled leu2-d gene that facilitates an ultra-high plasmid
copy number in the range of 200 to 400 per cell in
response to leucine starvation [33]. The combined fea-
tures of the PAP1500 expression system was chosen due
to our previous success with this system for high yield
expression of a variety of eukaryotic membrane proteins
[30-32,34].
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Figure 1 Structural model of the 1159 amino acids long hERG α-subunit. The figure is based on data from http://www.uniprot.org/uniprot/
Q12809 and plotted into textopo. The light gray area visualizes the lipid membrane. The 400 amino acids long N-terminal contains a PAS domain
(residues V41-H70), a PAC domain (residues R92-D144), a compositional bias poly prolin stretch (residues P297-P300) all in sky blue and a
phosphorylation site at residue S320 (green). The channel part of the protein consists of the six transmembrane domains (S1-S6). The charged
residues in segment 4 responsible for voltage sensing (residues K525,R528,R531,R534,R537,K538 and R541) are marked in light blue. A predicted
glycosylation site at residue N598 is labeled with a branch. The canonical SVGFG signature motif of the selectivity filter (residues S624- G628) located
in the loop between segment 5 and 6 is shown in wild strawberry. The intramembrane region of the protein may actually span from residue
612-632, but here only residues S621-N629 are shown residing within the membrane. The C-terminal cyclic nucleotide binding like domain (cNBD)
is marked in spring green and spans residues P742 - L842.
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Figure 2 Structural map of the hERG-TEV-GFP-His8 and
hERG-His10 expression plasmids. Abbreviations used: CG-P, a
hybrid promoter carrying the GAL10 upstream activating sequence
fused to the 5′ non-translated leader of the cytochrome-1 gene; T,
Tobacco Etch Virus (TEV) cleavage site; GFP-His8, yeast enhanced GFP
cDNA fused to eight histidine codons; 2μ, the yeast 2 micron origin of
replication; leu2-d, a poorly expressed allele of the β-isopropylmalate
dehydrogenase gene; bla, a β-lactamase gene; pMB1, the pMB1
origin of replication; URA3, the yeast orotidine-5′-phosphate
decarboxylase gene. Rapid construction of expression plasmids was
carried out by in vivo homologous recombination in S. cerevisiae.
S. cerevisiae produces functional membrane integrated
hERG channels
Before developing optimal expression and purification
protocols we found it crucial to analyse whether S. cere-
visiae has the capacity to assemble the homotetrameric
hERG channel in a functional form in the plasma mem-
brane and to determine if presence of the TEV-GFP-
His8 tag interferes with hERG functionality. To address
these issues we investigated the ability of the TEV-
GFP-His8 or His10 tagged hERG channel to complement
the potassium requirement of the trk1, trk2 yeast
strain PAP7111 at 11 different KCl concentrations. To
relate the complementation capacity of the hERG chan-
nels to natural yeast endogenous potassium transport we
included a wild type yeast strain in the growth assays.
The growth curves in Figure 3 show that wild type yeast
cells grew at extremely low potassium concentrations,
even in presence of only the potassium contamination
present in the chemicals used to prepare the growth
medium. In contrast yeast cells producing hERG-TEV-
GFP-His8, hERG-His10 protein or no hERG protein did
not show any growth at KCl concentrations below 2 mM.
However, yeast cells producing either of the two hERG
fusions grew significantly faster at potassium limited
conditions than strain PAP7111 harbouring the expres-
sion vector pEMBLyex4. Thus, PAP7111 producing the
fusions grew at 5 mM and 10 mM KCl, whereas no or
negligible growth was detected for PAP7111 harbour-
ing the pEMBLyex4 expression vector. At 100 mM the
three PAP7111 transformants proliferated with almost the
same growth rate. This shows that the heterologously
expressed hERG channels are functional and suggests
that the native tetrameric structure accumulates in the
yeast plasma membrane. Furthermore, since both the
TEV-GFP-His8 and the His10-fusions complements the
potassium transport defect of PAP7111 equally well, we
conclude that the TEV-GFP-His8 tag does not influence
channel activity or membrane targeting to any detectable
extent.
A highmembrane density of hERG-TEV-GFP-His8 is
obtained at 15°C
In order to maximize production of recombinant hERG
we used our production strain PAP1500 [30] and identi-
fied the expression conditions giving the highest hERG-
TEV-GFP-His8 membrane density. We therefore deter-
mined the kinetics of fluorescence accumulation in crude
membranes isolated from PAP1500 cells induced for
expression at 15°C or 30°C. Based on previous experience
[31,32] these temperatures were selected as expression at
15°C usually improves yield and quality of recombinant
membrane proteins and 30°C is the optimal temperature
for yeast growth. The accumulation profiles in Figure 4
show that production at 15°C caused hERG-TEV-GFP-
His8 to accumulate to a high membrane density that
stabilized over time, whereas at 30°C fluorescence peaked
after 24 hours at a much lower level and subsequently
declined. Production at 15°C resulted in accumulation of
80 pmol hERG/mg protein in crude membranes, corre-
sponding to 1.6% of the total cellular membrane protein
content.
HERG-TEV-GFP-His8 accumulates in the plasmamembrane
In native tissue the hERG channel is located in
the plasma membrane and as seen in Figure 5 live
cell bioimaging revealed that recombinant hERG-
TEV-GFP-His8 expressed in our production strain
PAP1500 also localized to the yeast plasma membrane.
Membrane-integrated accumulation of the hERG-
TEV-GFP-His8 fusion also indicates that hERG was
correctly folded and functional [35] in our production
strain.
HERG is N-glycosylated in S. cerevisiae
It has previously been shown that hERG is N-glycosylated
when produced in HEK293 cells [36]. To address
whether hERG-TEV-GFP-His8 produced in S.cerevisiae
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Figure 3 Yeast complementation assay. Growth in microplates at room temperature of the trk1, trk2 yeast strain PAP7111 expressing
hERG-TEV-GFP-His8 (green), hERG-His10 (red), no hERG channel (black) or the yeast wild type strain BY4741 (blue) for 96 hours in presence of the
indicated KCl concentrations.
is N-glycosylated we treated crude membranes with
Endo-glycosidase H and analyzed the digestion by
SDS-PAGE and in-gel fluorescence. Data in Figure 6
show that hERG is also N-glycosylated in S. cere-
viseae as Endoglycosidase-H treatment increased the elec-
trophoretic mobility of hERG-TEV-GFP-His8. The data
also show that N-glycosylation can be removed com-
pletely under the non-denaturing conditions applied in
Figure 6.
Astemizole binds with high affinity to membrane
embedded hERG with a single binding site per tetramer
To test the quality of membrane embedded hERG-TEV-
GFP-His8 in PAP1500 we determined the affinity and
capacity for Astemizole binding to crude membranes iso-
lated from yeast cells induced for hERG production at
15 ◦C. Astemizole was selected because it is a known spe-
cific hERG ligandwith high affinity and binding capacity is
known to correlate with patch clamp electrophysiological
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Figure 4 Time and temperature dependent accumulation of hERG-TEV-GFP-His8. A) Exponentially growing cells cultivated at room
temperature in expression medium until OD450 = 1.0 were separated in two. One half was transferred to 15°C while the other half was inoculated at
30°C. After 15 minutes of thermo-equilibration, production of hERG-TEV-GFP-His8 was induced by addition of Galactose (T = 0). Fluorescence was
determined in duplicates of crude membranes isolated from yeast cells induced for the indicated periods of time at either 15°C (blue line squares) or
30°C (red line circles). Fluorescence was translated into pmol hERG protein/mg total membrane protein using a GFP standard curve. Standard
deviations of duplicates are shown as error bars. B) In-gel fluorescence of 80 μg crude membranes prepared from the cultures induced at 15°C used
in figure A. C) In-gel fluorescence of 80 μg crude membranes prepared from the cultures induced at 30°C used in figure A. Lanes are marked with
time of hours post induction.
Figure 5 Live cell bioimaging of PAP1500 yeast cells expressing the hERG-TEV-GFP-His8 fusion protein. Yeast cells were grown in expression
medium at room temperature, transferred to 15°C and induced with 2% Galactose for 24 hours. A, GFP fluorescence; B, differential interference
contrast image (DIC).
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Figure 6 Endo-H treatment of crude yeast membranes under
non-denaturing conditions. Crude yeast membranes (80 μg) were
treated with Endo-H as described in methods in a non denaturing
buffer at 4°C over night. Untreated crude membranes (lane 1) or
Endo-H treated membranes (lane 2) were separated by SDS-PAGE
and analyzed by in-gel fluorescence. The only bands visible are the
hERG-TEV-GFP-His8.
measurements [37,38]. It can be seen from Figure 7 that
the dissociation constant, KD, for Astemizole binding was
15 nM while the binding capacity was estimated to 28
pmol/mg crude membrane protein. The high affinity indi-
cates that the hERG channel is correctly assembled in the
yeast plasma membrane and the binding capacity of 28
pmol/mg crude membrane protein fits quite well with a
single binding site per tetramer as the hERG-GFP protein
Figure 7 Concentration dependent binding of [3H] Astemizole
to crude membranes. Crude membranes corresponding to 200 μg
total membrane protein content were incubatedwith [3H]-Astemizole
in ranges of 0.5 - 20 nMwith andwithout a surplus of 10μMunlabeled
Astemizole at 15°C for 2 hours. Membrane bound ligand was
quantified by liquid scintillation counting and normalized to sample
volumes and protein content to determine total (blue squares),
unspecific (open triangles) and specific binding (red triangles) as pmol
bound [3H]-Astemizole/mg crude membrane protein. Nonlinear
regressionwas used to fit the experimental data to aMichaelis-Menten
equation as described in Methods.
density was estimated to 80 pmol/mg total protein in
crude membranes.
Fos-Choline-12 efficiently solubilizes hERG-TEV-GFP-His8
To find a suitable detergent for solubilization of the hERG-
TEV-GFP-His8 fusion, a solubilization screen was set up
with eight different detergents. Based on previous expe-
rience [32] solubilization was carried out in a mixture
of detergent and cholesteryl-hemisuccinate (CHS) to sta-
bilize the hERG-TEV-GFP-His8 fusion during and after
extraction from the membranes. Figure 8 shows that a
protein:FC-12:CHS ratio of 1:3:1.5 (w/w/w) most effi-
ciently solubilized the channel from crude yeast mem-
branes, yielding approximately 40% solubilized protein.
Three subsequent solubilization experiments using FC-12
and CHS gave on average 48% solubilization of hERGwith
a standard deviation of 9% (data not shown). The remain-
ing detergent:CHS mixes only resulted in approximately
5% solubilization of the hERG channel.
FSEC reveals that CHS and Astemizole improve the quality
of solubilized hERG-TEV-GFP-His8
To identify conditions that improve the quality of solubi-
lized hERG-TEV-GFP-His8 we performed FSEC analysis
on membranes solubilized in presence or absence of KCl,
CHS and Astemizole. As seen from Figure 9 addition of
CHS increased solubilization efficiency and resulted in
an almost monodisperse elution profile with a reduced
amount of aggregated protein eluting in the void volume.
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Figure 8 Detergent screen of crude membranes from PAP1500
producing hERG-TEV-GFP-His8 at 15°C.Membrane proteins were
solubilized as described in the Methods section, at the indicated
detergent/protein ratios and a cholesteryl-hemisuccinate
concentration of 4.25; 2.8 or 2 mg/ml for the 3 ratios, respectively.
Abbreviations; FC-12, Fos-Choline-12; LDAO lauryldimethylamine
N-oxide; CYMAL5, 5-Cyclohexyl-1-pentyl-β-D-maltoside ; DDM,
n-Dodecyl-β-D-maltopyranoside; DM, n-Decyl-β-D-maltopyranoside;
C12E8, Octaethylene glycol monododecyl ether; CHAPS,
3-[(3-cholamidopropyl) dimethylam-monio] -1-propanesulfonate; OG,
n-Octyl-β-D-glucopyranoside. Solubilization was determined as GFP
fluorescence of solubilized protein normalized to GFP fluorescence in
the crude membranes used for solubilization.
Presence of 5 mM KCl during solubilization did not
increase protein quality irrespective of presence of CHS.
Presence of 1 μM Astemizole during solubilization and
size exclusion chromatography or only during the chro-
matographic step resulted in a further improved FSEC
profile showing a narrower and more symmetrical elution
peak (Figure 9E and F). This demonstrates that Astemizole
binds quantitatively to the solubilized hERG channel and
that the solubilized channel has maintained its tetrameric
structure. This is further supported by the fact that the
156 kDa hERG-TEV-GFP-His8 fusion eluted as an approx-
imately 620 kDa protein according to the elution profile of
the MW standards, even though the amount of detergent
in the hERG detergent complex is unknown. The observa-
tion that presence of Astemizole was only required during
size exclusion chromatography to improve the FSEC pro-
file indicates that the broader FSEC profile observed in
presence of only FC-12 and CHSmay reflect the flexibility
of the channel and not partly inactivated channels.
Ni-affinity purification results in highly pure
hERG-TEV-GFP-His8 protein
To purify the hERG-TEV-GFP-His8 fusion we solubi-
lized crude membranes in FC-12:CHS at a protein:
detergent:cholesterol ratio of 1:3:1 (w/w/w). As seen from
Figure 10 the hERG-TEV-GFP-His8 protein eluted as a
major peak at 100 mM imidazole. In-gel fluorescence
and Coomassie staining of SDS-PAGE separated peak
fractions revealed a high degree of purity (Figure 10B
and 10C) since only full-length fluorescent protein with a
molecular weight of the expected 156 kDa was visible in
the Coomassie stained gel.
Purified recombinant hERG binds Astemizole
To study the quality of detergent solubilized and puri-
fied hERG-TEV-GFP-His8 we determined the affinity and
capacity for Astemizole binding. Data in Figure 11 show
that the purified channel was able to bind Astemizole
with an affinity of 13.8 nM and a capacity of 1.1 nmol/mg
fusion protein. Since the theoretical binding capacity for
the pure 156 kDa hERG-TEV-GFP-His8 fusion amounts
to 1.4 nmol/mg fusion protein, this strongly suggests
that the native tetrameric structure was preserved during
detergent solubilization and purification. The discrepancy
between the actual and theoretical binding capacity may
be explained by the presence of protein contaminants
in the affinty purified hERG-TEV-GFP-His8 preparation.
The binding affinity for Astemizole measured for the
detergent solubilized hERG-TEV-GFP-His8 fusion and for
the membrane embedded fusion were similar; 13.8 nM
and 15.0 nM respectively. In contrast to the ligand binding
curve in Figure 7 based on membrane embedded hERG-
TEV-GFP-His8, the binding curve for the purified protein
did not follow a Michaelis-Menten equation but turned
out to be sigmoid, which is characteristic of cooperative
protein ligand interactions.
TEV-cleavage releases the GFP-His8 tag from hERG
Peak fractions from the Ni-NTA affinity purification in
Figure 10 were used for TEV protease digestion at a
TEV:protein ratio of 10:1 (w/w) at room temperature.
Figure 12 shows the result from in-gel fluorescence (A)
and Coomassie staining (B) of an SDS-PAGE separated
TEV digestion. The hERG-TEV-GFP-His8 fusion was
completely digested resulting in appearance of the fluo-
rescent GFP-His8 tag as a 36 kDa protein band, whereas
the full-length fusion was no longer visible (Figure 12A).
A 127 kDa protein corresponding to the hERG protein
released by TEV digestion was however visible in the
Coomassie stained gel (Figure 12B, lane 2).
Discussion
Potassium channels are present throughout all kingdoms
and are crucial for conduction of electrical signaling [39].
Their fundamental role in cell homoeostasis makes some
potassium channels obvious drug targets [40] while inter-
fering with the activity of others may be lethal [41].
The hERG channel belongs to the latter category as
inhibition of this channel can cause sudden death in
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Figure 9 FSEC profiles of solubilized crude membranes.Membranes were isolated from yeast cells induced for hERG-TEV-GFP-His8 production
at 15°C for 48 hours. Membranes were solubilized at a concentration of 2 mg/ml in FC-12 at a 3:1 detergent to protein ratio without any supplement
(A), supplemented with 5 mM KCl (B), supplemented with 5.1 mg/ml cholesteryl-hemisuccinate (C) or both (D), with cholesteryl-hemisuccinate
and 1 μM Astemizole (E) or with cholesteryl-hemisuccinate without Astemizole (F) as described in Methods section. Solubilizations E and F were
separated in presence of 1 μM Astemizole. Solubilized membrane proteins were separated on a Superose 6 10/300 GL column. Molecular weight
markers (GE Healthcare Life Science) separated on the same column eluted as follows: Blue Dextran 2000, 2000 kDa at void volume 8 ml (marked
with an asterisk), Thyroglobulin 669 kDa at 12.5 ml, Ferritin 440 kDa at 14.5 ml, Aldolase 158 kDa at 16.3 ml, Conalbumin 75 kDa at 17.3 ml,
Ovalbumin 44 kDa at 17.6 ml.
otherwise healthy individuals [14]. High resolution struc-
tures of potassium channels are therefore eagerly pursued.
However, their complex structure and conformational
flexibility have hampered generation of high resolution
3D structures through crystallization and X-ray diffrac-
tion. Exceptions include a few voltage gated potassium
channels such as the shaker channel from Drosophila
and KvAP from the archae, Aeropyrum pernix [21,22].
Despite availability of milligram amounts of bacterial
potassium channels, it has been challenging to obtain
crystal structures of these, due to protein aggregation
during purification and crystallization. The flexible volt-
age sensing domain is potentially the molecular cause
of these challenges [21]. The only structure available for
members of the family of 6-TM mammalian potassium
channels to which hERG belongs is that of rat Kv1.2 [22].
Successful crystallization of rat Kv1.2 reflects that this
is the only channel which has been successfully overex-
pressed and purified in the amount and quality required
for initiating crystallization screens. Previous attempts
to overexpress and purify hERG highlights these prob-
lems as purification of recombinant native, tetrameric
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Figure 10 Purification of hERG-TEV-GFP-His8 by Ni-affinity chromatography. HERG-TEV-GFP-His8 was solubilized in FC-12/CHS and incubated
with Ni-resin over night at 4°C, as described in the Methods section. The Ni-resin was poured on a column and hERG-TEV-GFP-His8 was eluted from
the Ni-resin using the indicated imidazole step gradient (blue). Fluorescence was measured in each fraction to estimate the elution profile of the
hERG-fusion (pink). B) In-gel fluorescence of Ni-affinity purified hERG-TEV-GFP-His8 separated by SDS-PAGE in an 8% gel. Lanes contain fractions
13-21 from A. C) Coomassie stain of the SDS-PAGE gel in B.
Figure 11 Binding affinity and capacity of [3H]-Astemizole to
purified hERG-TEV-GFP-His8. 0.1 μg affinity purified hERG was
incubated with [3H]-Astemizole in ranges of 0.5 - 20 nm with or
without a surplus of 10 μM unlabelled Astemizole at 15°C for 2 hours.
[3H]-Astemizole binding was quantified by scintillation counting as
described in the Methods section. All solutions contained 1.5 mg/ml
FC-12 and 0.5 mg/ml CHS. The experimental data were fitted to a
sigmoid curve as described in the Methods section.
Figure 12 TEV digestion of hERG-TEV-GFP-His8. Peak fraction 17
from the Ni-affinity purification in Figure 10 was dialyzed for 8 hours
at 4°C and subsequently digested over night at room temperature at
a hERG-TEV-GFP-His8: TEV ratio of 1:10 (w/w). A) In-gel fluorescence of
undigested hERG-TEV-GFP-His8 protein (lane 1); TEV digested
hERG-TEV-GFP-His8 protein (lane2) . B) Coomassie stain of the gel in
A. The 156 kDa band represents the hERG-TEV-GFP-His8 fusion, the
127 kDa band is the tag-free hERG, the 36 kDa band is the GFP-tag
liberated after TEV digestion and the 25 kDa band is TEV protease.
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hERG has been unsuccessful, despite investigation of a
number of host organisms. Purification of recombinant
hERG from Sf9 insect cells resulted in nonfunctional
monomers [26]. However, the purified hERG monomers
were successfully used to generate a set of monoclonal
anti-hERG-antibodies [26] which may become of great
value for stabilizing the tetrameric hERG protein struc-
ture during purification and crystallization as demon-
strated in the KvAP channel study [21]. Direct expression
into biomimetic membranes, using a cell free system has
also been attempted, and proved efficient for the mem-
brane spanning part of hERG [29] but not for the full
length channel. A recent study succeeded in expressing
and purifying an artificially engineered tetrameric hERG
channel by introducing the dimerization domain from
the Gcn4 transcription factor. However this manipulated
hERG channel did not include the long N- and C-terminal
parts [28].
In order to produce full length, functional and
tetrameric hERG channels, we applied our yeast expres-
sion platform [30-32]. To ease quantification of recom-
binant hERG, determination of subcellular localization
and identification of optimal solubilization and purifica-
tion conditions, we produced hERG C-terminally fused
to a GFP-His8 tag [35]. The combination of an ultra-high
copy number expression vector, a yeast strain overpro-
ducing the Gal4 transcriptional activator and expression
at 15°C in amino acid supplemented medium caused the
hERG subunit to accumulate to a membrane density of
1.6%. This is in fact an extraordinary high membrane
density as the 7TM receptors that have been success-
fully crystalized were purified from a membrane density
of 0.2% [42]. Thus, production in our 10 L computer con-
trolled bioreactor should generate in the vicinity of 100
milligram membrane embedded hERG channel protein
(not shown).
In native tissue the hERG channel is localized to the
plasma membrane. It was therefore encouraging that the
recombinant hERG maintained its localization in yeast
(Figure 5) as this is a good indicator of correct folding
and assembly. One of the advantages of using a micro-
bial expression host and particular S. cerevisiae is that
an almost complete set of knock-out strains exists [43].
Availability of these strains allows application of simple
complementation experiments to identify conditions that
allow functional expression of many recombinant pro-
teins. We took advantage of this by showing that both
the hERG-TEV-GFP-His8 and the hERG-His10 fusion
complemented the high potassium requirement of a S.
cerevisiae strain carrying knock-outs of the TRK1 and
TRK2 potassium transporters (Figure 3). Yeast is there-
fore able to assemble the hERG-TEV-GFP-His8 chan-
nel correctly in the plasma membrane and the GFP
part does not prevent channel activity. However, as it
is seen in Figure 3 an extra cellular concentration of
5 mM is required for complementation. This concen-
tration is high compared to the extremely low potas-
sium concentration required for growth of wild type
yeast (Figure 3). In accordance with previous results [44]
the wild type showed significant growth in presence of
nothing but the trace ammounts of potassium inadver-
tently contaminating the chemicals used for preparing
the growth medium. The rather high potassium con-
centration required for complementation by the hERG
channel probably reflects that the membrane poten-
tial of around -200 mV for a wild type yeast strain
is further hyperpolarized in the trk1, trk2 yeast
strain [45].
To ensure high yield, our high protein accumulation
production strain PAP1500 was used for expression of
hERG-TEV-GFP-His8. HERG produced in yeast turned
out to be N-glycosylated as shown previously for HEK293
produced hERG protein [36]. We were however able to
remove the glycosylation under non-denaturing condi-
tions which is important in relation to crystallization. To
ascertain that the hERG-channels produced in PAP1500
were functional too, we combined equilibrium binding
to Astemizole [37] with the advantages of the GFP tag.
Equilibrium binding to [3H]-Astemizole made it possi-
ble to quantify the density of correctly folded, tetrameric
hERG channels, while presence of the C-terminal GFP
allowed us to quantify the density of hERG-TEV-GFP-
His8 fusion-proteins in crude membranes. The observa-
tion that the Astemizole binding capacity approached one
per four hERG-TEV-GFP-His8 protein chains is a strong
indication that the great majority of the accumulated
channels is correctly folded and therefore also functional
in the expression strain PAP1500, because the capacity
for Astemizole binding has been shown to correlate well
with patch clamp electrophysiological measurements [38].
In conclusion, our yeast expression platform assembles
functional hERG channels in the plasma membrane in a
quantity and quality suitable for large scale production
and purification.
The next hurdle for successful purification of hERG
is to identify solubilization conditions that maintain the
functional, tetrameric structure. Based on our experi-
ence with the expression platform [32] we performed a
solubilization screen using a mixture of detergent and
cholesteryl-hemi-succinate. In agreement with a previ-
ously described solubilization screen including more than
70 detergents [26] we found that FC-12 was the only deter-
gent that solubilized the recombinant hERG channel at an
acceptable level. Although some proteins have been crys-
tallized in FC-12 [46] it may however not be the most
appreciated detergent for crystallization as it is generally
regarded a quite harsh detergent [47]. However, our FSEC
analysis showed that a very sub-optimal elution profile
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indicative of aggregated protein could be rescued by sol-
ubilization in presence of CHS and further improved by
presence of Astemizole (Figure 9) resulting in an almost
perfect symmetrical FSEC elution profile, indicative of
channels that are highly qualified for initiating crystal-
lization trials. The fact that CHS improved the FSEC
profile of hERG channels so dramatically demonstrates
the important role of CHS for maintaining membrane
protein structure. The further improvement in monodis-
persity observed in presence of Astemizole is also very
encouraging as it shows that all the solubilized pro-
tein has maintained its ability to bind this specific and
high-affinity ligand. This strongly supports that the sol-
ubilization conditions we have developed maintain the
functional tetrameric structure, in accordance with the
elution of the solubilized hERG channel as a 620 kDa
protein. A tetrameric structure is necessary for activ-
ity, and therefore an indication of functionality [38]. To
our knowledge this is the first time hERG has been
purified as a full length tetramer. Ni-affinity purification
of FC-12/CHS solubilized hERG-TEV-GFP-His8 resulted
in a very pure preparation as indicated by SDS-PAGE
analysis as in-gel fluorescence and Coomassie staining
showed a single protein band with the expected molec-
ular weight of 156 kDa. No degradation products were
observed indicating that the solubilization conditions did
not expose the hERG-TEV-GFP-His8 channels to yeast
proteases.
The ability to produce the hERG channel to a high
membrane density is only relevant if the purified pro-
tein has preserved its biological activity. It was therefore
encouraging that the capacity of the purified channel
for Astemizole binding approached one binding site per
four hERG-TEV-GFP-His8 protein chains as the binding
capacity for this ligand has been shown to correlate well
with patch clamp electrophysiological experiments [38].
The fact that the purified hERG channels bound Astem-
izole confirms the FSEC results. Compared to the hyper-
bolic binding curve for membrane embedded hERG-TEV-
GFP-His8 (Figure 7) the binding curve to purified and
detergent solubilized hERG followed a sigmoid binding
curve (Figure 11). Sigmoid binding curves are character-
istic of cooperative binding of ligands to multi subunit
proteins. In this case though, the hERG sigmoid binding
may be explained by the different conformations that the
channel pore can attain (open, close, rotated and inter-
mediate) [48] and indicate that the detergent solubilized
channel pore is more flexible in detergent than in the
biological membrane.
Removal of the GFP-His8 tag by TEV cleavage may be a
prerequisite for obtaining crystal structures and we were
indeed able to remove the GFP-His tag quantitatively by
TEV digestion during removal of imidazole by dialysis
(Figure 12).
Conclusions
In conclusion, we describe a cost-effective, novel and
efficient solubilization and purification protocol, which
generates milligram amounts of correctly folded, full-
length hERG protein after production in S. cerevisiae.
The amount and in particular the quality of the produced
hERG channels is to our knowledge unprecedented and
presents a major breakthrough in the study of hERG,
which may facilitate further functional studies and struc-
ture determination through crystallization. Availability of
large amounts of prime quality hERG channels may also
accelerate studies of transfer of full length channel protein
into biomimetic membranes for sensor and separation
applications [49]. Such a setup may be used for rapid
screening to help exclude potential drugs with detrimen-
tal side effects at an early stage and restrict focus to
candidates without such effects.
Methods
Yeast strains
Production of tagged protein constructs for purification
was carried out in S. cerevisiae strain PAP1500 (α ura3-52
trp1::GAL10-GAL4 lys2-801 leu21 his3200 pep4::HIS3
prb11.6R can1 GAL) [30] while complementation stud-
ies were performed in PAP7111 (α ura3-52 his3 200
HIS 4-15 trk1 trk2::HIS3 PMA1::mcherry). PAP7111
was constructed by transformation of CY162 [50] with a
PCR fragment carrying the mCherry [51] coding region
flanked by 35 nucleotides used for homologous recombi-
nation with the chromosomal PMA1 locus. The wild type
strain BY4741 (a his31 leu20 met150 ura30) [52]
was used in the complementation studies, too.
Recombinant plasmid construction
A 3480 bp long yeast codon optimized hERG sequence
was purchased from Genscript, USA. To C-terminally
tag hERG with a Tobacco Etch Virus cleavage site
and a yEGFP-His8 sequence, we PCR amplified codon
optimized hERG cDNA with primers hERGfw 5′-
ACACAAATACACACACTAAATTACCGGATCAAT
TCTTTAAAACGAATGCCAGTTAGAAGAGG
TC-3′ and hERGrv 5′-AAAT TGACTTTGAAAATA-
CAAATTTTCACTACCTGGGTCACTACCG - 3′ and
yEGFP cDNA [32] with primers GFPfwTEV 5′-AAAATTT
GTATTTTCAAAGTCAATTTTCTAAAGGTGAAGAA
TTATTCACT-3′ and GFPHISdo 5′-CTT CAATGCTAT-
CATTTCCTTTGATATTGGATCATCTAATGGTGATG
GTGATGGTGATGGTGTTTGTACAATTCA-3′.
The emphasized nucleotides were used for in vivo
homologous recombination, the bold nucleotides are
identical or inverse complimentary to the template, the
text in between these two formattings in hERGfw is the
Kozak sequence from the yeast PMR1 gene and in the
GFPHISdo it is the His-tag. The TEV site is marked in
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italics. All PCR reactions were performed with AccuPol
DNA polymerase (Amplicon, Denmark). The hERG-TEV-
GFP-His8 expression plasmid was generated by in vivo
homologous recombination by transforming PAP1500
with hERG and GFP PCR products and SalI, HindIII
and BamHI digested pEMBLyex4 [53] expression vec-
tor, using the transformation protocol described by Gietz
and Schiestl [54]. The correct nucleotide sequence of the
expression construct was verified by DNA sequencing at
Eurofins MWGOperon, Germany.
Yeast complementation assay
PAP7111 cells harboring the pEMBLYex4 plasmid, the
hERG-TEV-GFP-His8 expression plasmid or the hERG-
His10 expression plasmid were cultured in SD medium
[32] supplemented with 100 mM KCl. The wild type
strain BY4741 was cultured in SD medium supplemented
with histidine, leucine, methionine and uracil. Cells were
subsequently harvested, washed thoroughly with 18 m
H2O to remove residual KCl originating from the ini-
tial growth medium and inoculated in TES-TRIS buffered
(pH 6.0) SD+SG medium at OD450 = 0.05 in 96 well
micro plates (Nunc, clear plastic) at KCl concentrations of
0, 0.1, 1, 2, 5, 10, 15, 20, 25, 30, 35 or 100 mM, respec-
tively. Growth was monitored 3 times a day for 5 days by
measuring OD450.
Recombinant hERG production
Yeast cells were cultured and induced to express hERG
as described by Scharff-Poulsen, P and Pedersen, PA [32]
In brief cells were inoculated in 5 ml synthetic minimal
(SD) medium supplemented with leucine and incubated
at 30°C O/N until saturation. The plasmid copy num-
ber in the yeast population was subsequently increased
by growth in medium lacking leucine. This culture was
used to inoculate 1 L of expression medium, which is SD
mediumwith glucose (0.5%w/v), glycerol (3% v/v), alanine
(20 mg/L), arginine (20 mg/L), aspartic acid (100 mg/L),
cysteine (20mg/L), glutamic acid (100mg/L), histidine (20
mg/L), lysine (30mg/L), methionine (20mg/L), phenylala-
nine (50mg/L), proline (20mg/L), serine (375mg/L), thre-
onine (200 mg/L), tryptophane (20 mg/L), tyrosine (30
mg/L) and valine (150 mg/L) to an OD450 of 0.05. The cul-
ture was incubated at room temperature until the OD450
reached 1.0, transferred to 15°C and supplemented with
induction medium (identical to the expression medium
described above except that 20% galactose has substituted
0.5% glucose) to a final concentration of 2% galactose.
The culture was incubated for at least 48 hours before
harvesting.
Live cell bioimaging
Localization of heterologously expressed GFP-tagged
hERG was determined by visualizing GFP fluorescence
in whole cells at 1000 × magnification, using a Nikon
Eclipse E600 microscope coupled to an Optronics Mag-
nafire model S99802 camera.
Deglycosylation
80 μg of crude membranes were incubated with 500 units
of Endo-H (New Biolabs, USA) at 4°C in Lysis buffer over
night alongside 80 μg of crude membranes in lysisbuffer
with no added Endo-H. Samples were separated in a 10%
SDS-PAGE gel at 150 V for 2 hours, and visualized by in-
gel fluorescence.
Temperature optimization of hERG production
Yeast cells were grown at room temperature as described
above in 1 L of expression medium. At OD450 = 1.0, half
of the culture was transferred to 15°C and the other to
30°C. After thermo equilibration, hERG production was
induced by adding 55 ml of induction medium. Samples
were collected 12, 24, 48, 72 and 96 hours post induction.
Crude membranes were isolated from cells harvested at
each time point and analysed by in-gel fluorescence using
a LAS 4000 (GE Healthcare, USA).
Membrane preparation
Crude yeast membranes were prepared by disrupting cell
pellets by glassbead vortexing [55]. Briefly, cell pellets
from 1 L cultures were resuspended in 10 ml ice cold lysis
buffer (25 mM imidazole, 1 mM EDTA, 1 mM EGTA,
10% glycerol (v/v) pH 7.5) with protease inhibitors (1
mM PMSF, 1 mM benzamidine, leupeptin (1 μg/ml), pep-
statin (1 μg/ml), chymostatin (1 μg/ml) and aprotinin (1
μg/ml)). Samples were vortexed 4 × 1 minutes with at
least 1 minute of cooling in between mixing. The liq-
uid phase was collected, and beads were washed several
times with lysis buffer generating samples of 50 ml total
volume. Cell debris was pelleted by centrifugation for 10
minutes at 3,000 rpm and 4°C in an SS-34 rotor. Crude
membranes were pelleted from the supernatant by ultra-
centrifugation for 1.5 hour at 40,000 rpm and 4°C in a 70TI
rotor. Crude membranes were resuspended in 3 ml lysis
buffer with protease inhibitors (as above), homogenized
in a Potter-Elvehjem homogenizer and stored at -80°C for
further use.
Protein and hERG-GFP quantification
Protein concentrations in crude membranes were
determined by the BCA assay [56] according to the
manufacturer′s specifications (Sigma, USA) using BSA as
a standard. The density of hERG-TEV-GFP-His8 in yeast
membranes was determined from the GFP fluorescence
emitted from 25 μg of total membrane protein mea-
sured in 96 well white microplates (Nucleon Nunc) after
adjustment of the volume to 200 μl with buffer (20 mM
phosphate pH 7.0, 200 mM NaCl, 10% glycerol, 10 mM
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Imidazole). Fluorescence was measured in a spectroflu-
orometer (Fluoroskan Ascent, Thermo Scientific) using
buffer as a blank. Excitation was at 485 nm and emission
at 520 nm. Fluorescence was converted to pmol hERG-
GFP from a standard curve generated from purified GFP
mixed with yeast membranes as previously established
[31,32].
Astemizole binding to crudemembranes
Crude membranes were used to assess the capability
of the recombinant hERG-GFP to bind the hERG lig-
and Astemizole, as described for HEK293 cells express-
ing hERG [38]. Aliquots of 200 μg crude membrane
protein in total volumes of 400 μl incubation buffer
(10 mM HEPES 130 mM NaCl, 60 mM KCl 0.8 mM
MgCl2 10 mM glucose 1 mM EGTA pH 7.4) sup-
plemented with protease inhibitors (1 mM PMSF, 1
mM Benzamidine, 1μg/ml Leupeptin, Chymostatin, Pep-
statin and Aprotinin) were mixed with [3H]-Astemizole
concentrations ranging from 0.5 - 20 nM. Unspecific
binding was determined in the presence of 10 μM non-
radiolabeled Astemizole. Binding was done at 15°C for 2
hours with slow speed shaking, and samples kept on ice
here on after. Protein-ligand complexes were separated
from free ligand by filtration of 200 μl sample through
Whatman GF/B glass fiber filters presoaked in 0.3%
polyethyleneimine and washed once in 1 ml ice cold
wash buffer (25 mM Tris-HCl, 130 mM NaCl, 5 mM
KCl, 0.8 mM MgCl2, 0.05 mM CaCl2, pH 7.4) with pro-
tease inhibitors. Subsequently filters were washed 6 times
with 1 ml ice cold wash buffer using vacuum filtration,
and bound ligand was detected using a Perkin Elmer
Tri-Carb 2910 TR liquid scintillation counter. 50 μl of
unfiltered sample was used for determination of total
CPM counts. A subsequent BCA protein determina-
tion assay was done on all samples to allow for correc-
tions due to any protein loss during the binding assay.
After calculating total, unspecific and specific binding the
resulting graph was analyzed using the Sigmaplot non-
linear regression tool, ligand binding; one-site saturation
(f = Bmax*abs(x)/(Kd + abs(x)) to estimate binding affinity
and capacity.
Astemizole binding to purified protein
0.1 μg of affinity purified hERG-TEV-GFP-His8 protein
was used to estimate binding affinity and binding capacity.
Purified hERG protein was incubated with increas-
ing ammounts of [3H]-Astemizole, filtered and [3H]-
Astemizole binding determined by scintillation counting.
Unspecific binding was determined in presence of 10
μM non-radioactive labelled Astemizole. All solutions
contained 1.5 mg/ml FC-12 and 0.5 mg/ml CHS. Experi-
mental data were analysed in Sigmaplot using a sigmoid 3
parameter curve-fit (f=a(1+exp(-(x-x0)/b).
Detergent screening
Crude membranes were incubated in buffer B (25 mM
Tris-HCl, 10 mM Imidazole, 0.5 M NaCl, 10% glycerol,
pH 7.6) supplemented with protease inhibitors (1 mM
PMSF, 1 mM Benzamidine and 1μg/ml Leupeptin,
Chymostatin, Pepstatin and Aprotinin respectively)
at protein:detergent:CHS ratios (w/w) of 1:2:0.7; 1:3:1
or 1:4:1.4 The screen included detergents FC-12, n-
dodecylphosphocholine; LDAO, Lauryldimethylamine
N-oxide; Cymal-5, 5-cyclohexyl-1-pentyl-β-D-maltoside;
DDM, n-dodecyl-β-D-maltopyranoside; DM, n-decyl-β-D-
maltopyranoside; C12E8, Octaethylene glycol monododecyl
ether; CHAPS, 3-[(3chol-amidopropyl)-dimethylammonio]-
1-propane sulfonate/ N,N-dimethyl-3-sulfo-N-[3-[[3a,5b,
7a,12a)-3,7,12- tri - hydroxy-24-oxocholan-24-yl]amino]
propyl]-1-propana-miniumhydroxide andOctyl glucoside.
All detergents were of Anagrade quality and purchased
from Affymetrix, UK. Solubilization was performed at
slow rotation at 4°C for 1 hour. Solubilized hERG-GFP
channel protein was separated from un-solubilized cell
debris by ultra-centrifugation at 70,000 rpm for 30 min-
utes at 4°C in a Beckman Optima™TLX ultracentrifuge
fitted with an S.N. 96U 826 rotor. Fluorescence was
detected in microplates in a spectrofluorometer (Flu-
oroskan Ascent, Thermo Scientific) using buffer as a
blank. Excitation was at 485 nm and emission at 520 nm.
Solubilization efficiency was etimated as fluorescence
in the supernatant divided by fluorescence in the crude
membranes used for solubilization.
FSEC
Solubilized crude membranes were analyzed by fluores-
cence size exclusion chromatography (FSEC) on a Super-
ose 6 10/300 column attached to an A¨KTA Purifier (GE
Healthcare, USA), using FSEC buffer (20 mM TRIS-HCl,
0.15 M NaCl, 0.03% DDM). 1 μM Astemizole was added
to the buffer in experiments involving Astemizole. The
effluent from the Superose 6 10/300 column was cou-
pled to a fluorescence detector (Shimadzu Prominence
RF-20A), to measure fluorescence and visualize the elu-
tion profile of the GFP tagged hERG channel. To estimate
the molecular weight of the solubilized hERG-TEV-GFP-
His8 protein, we used the HMW calibration kit from GE
Healthcare dissolved at 20 mg/ml in FSEC buffer. The
molecular masses were: Ovalbumin 43 kDa; Conalbumin
75 kDa; Aldolase 158 kDa; Ferritin 440 kDa; Thyroglobu-
lin 669 kDA; Blue Dextran 2000 kDa. The elution volume
for Blue Dextran defined the void volume.
Ni-NTA affinity purification
For purification, the hERG-GFP protein was solubilized in
buffer B at a protein:FC-12:CHS ratio of 1:3:1 (w/w/w) at
slow rotation at 4°C for 1 hour. Non-solubilized material
was pelleted at 70,000 rpm in the Beckmann Optima
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TL200 ultracentrifuge for 30 minutes at 4°C. Solubi-
lized membranes were diluted in buffer B with protease
inhibitors to a detergent concentration of 0.75 mg/ml cor-
responding to 1.5 times CMC for Fos-choline-12 and a
CHS concentration of 0.26 mg/ml, incubated over night
with 1 ml of Ni-NTA Agarose (Qiagen, Germany) at 4°C
with slow magnetic stirring. The Agarose slurry was sub-
sequently loaded onto a 2 ml CellThru disposable column
(Clontech, USA). After collection of the run through, the
column was washed with Buffer B containing 10 mM,
30 mM, 100 mM, 250 mM or 500 mM imidazole. All
buffers contained 0.75 mg/ml FC-12 and 0.26 mg/ml CHS
Fluorescence in each fraction was quantified using a spec-
trofluorometer (Fluoroskan Ascent, Thermo Scientific)
using buffer as a blank. Excitation was at 485 nm and
emission at 520 nm.
TEV cleavage
Purified hERG-GFP-His8 fusion protein were digested
O/N in snakeskin dialysis bags (Thermo Scientific, USA)
with dialysis buffer (20 mM phosphate pH 7.0 200 mM
NaCl 0.075% (w/v) FC-12 0.026% (w/v) CHS) and TEV
protease [32] at room temperature with a protein to TEV
ratio of 1:10 (w/w). Digestion efficiency was estimated by
in-gel fluorescence followed by Coomassie staining.
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